Frequently Asked Questions about Glaukos Corporation (GKOS)

Name: Glaukos Corporation (GKOS) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Glaukos Corporation (GKOS) do?

Accepted Answer

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outf...

Question 2

Is Glaukos Corporation (GKOS) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of GKOS reveals an Altman Z-Score of 15.49 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($0.51B most recent), help investors decide if GKOS fits their risk profile.

Question 3

What is the current P/E ratio for GKOS?

Accepted Answer

As of the latest trading session, Glaukos Corporation (GKOS) has a trailing P/E ratio of -35.75.

Question 4

Who is the CEO of Glaukos Corporation?

Accepted Answer

The current Chief Executive Officer of Glaukos Corporation is Thomas William Burns.

Question 5

What was GKOS's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Glaukos Corporation reported annual revenues of $0.51B (2025), $0.38B (2024), $0.31B (2023), $0.28B (2022), $0.29B (2021) respectively.

Question 6

Does GKOS pay a dividend?

Accepted Answer

Glaukos Corporation does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does GKOS have?

Accepted Answer

In its latest reporting period, Glaukos Corporation generated $-0.05B in Free Cash Flow against a total debt load of $0.14B.

Question 8

What is the Price-to-Book (P/B) ratio of Glaukos Corporation?

Accepted Answer

The Price-to-Book (P/B) ratio for Glaukos Corporation (GKOS) is currently 10.23.

Question 9

What is the Price-to-Sales (P/S) ratio of GKOS?

Accepted Answer

Based on trailing twelve-month data, Glaukos Corporation (GKOS) trades at a Price-to-Sales (P/S) ratio of 13.36.

Question 10

What is Glaukos Corporation's Return on Equity (ROE)?

Accepted Answer

Glaukos Corporation (GKOS) has a Return on Equity (ROE) of -25.41%, representing its profitability relative to shareholder equity.

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	893.5M	237.3M	656.2M	139.6M	48.8M
2024-12	974.8M	207.8M	766.9M	105.9M	-63.8M
2023-12	940.4M	478.6M	461.8M	383.7M	290.3M
2022-12	1.1B	544.2M	530M	382.9M	263.4M
2021-12	1.1B	541.7M	587.2M	383.4M	282.7M

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	893.5M	237.3M	656.2M	139.6M	48.8M
2024-12	974.8M	207.8M	766.9M	105.9M	-63.8M
2023-12	940.4M	478.6M	461.8M	383.7M	290.3M
2022-12	1.1B	544.2M	530M	382.9M	263.4M
2021-12	1.1B	541.7M	587.2M	383.4M	282.7M